NCT06029972: An ongoing trial by Gilead Sciences
This trial is ongoing. It must report results 1 year, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06029972 |
|---|---|
| Title | A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 5, 2023 |
| Completion date | April 30, 2026 |
| Required reporting date | April 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |